[{"address1": "1500 District Avenue", "city": "Burlington", "state": "MA", "zip": "01803", "country": "United States", "phone": "617 600 7373", "website": "https://www.minervaneurosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. Remy  Luthringer Ph.D.", "age": 62, "title": "Executive Chairman & CEO", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 1274649, "exercisedValue": 0, "unexercisedValue": 34200}, {"maxAge": 1, "name": "Mr. Geoffrey Robin Race F.C.M.A., M.B.A.", "age": 62, "title": "President", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 913302, "exercisedValue": 0, "unexercisedValue": 28880}, {"maxAge": 1, "name": "Mr. Joseph  Reilly", "age": 48, "title": "Senior VP & COO", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 460999, "exercisedValue": 0, "unexercisedValue": 632717}, {"maxAge": 1, "name": "Mr. William B. Boni", "age": 71, "title": "Vice President of Investor Relations & Corporate Communications", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Michael  Davidson M.D.", "age": 73, "title": "Chief Medical Officer", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 657466, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.47, "open": 2.4514, "dayLow": 2.42, "dayHigh": 2.46, "regularMarketPreviousClose": 2.47, "regularMarketOpen": 2.4514, "regularMarketDayLow": 2.42, "regularMarketDayHigh": 2.46, "beta": 0.129, "forwardPE": -1.2019211, "volume": 9179, "regularMarketVolume": 9179, "averageVolume": 16251, "averageVolume10days": 15880, "averageDailyVolume10Day": 15880, "marketCap": 17133856, "fiftyTwoWeekLow": 2.26, "fiftyTwoWeekHigh": 13.49, "fiftyDayAverage": 2.67078, "twoHundredDayAverage": 3.66545, "currency": "USD", "enterpriseValue": 72761256, "floatShares": 5436884, "sharesOutstanding": 6993410, "sharesShort": 7205, "sharesShortPriorMonth": 7712, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.22257, "heldPercentInstitutions": 0.30018, "shortRatio": 0.63, "shortPercentOfFloat": 0.0018000001, "impliedSharesOutstanding": 7022360, "bookValue": -6.362, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -33645196, "trailingEps": -4.4, "forwardEps": -2.03, "lastSplitFactor": "1:8", "lastSplitDate": 1655769600, "enterpriseToEbitda": -2.777, "52WeekChange": -0.39454097, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NERV", "underlyingSymbol": "NERV", "shortName": "Minerva Neurosciences, Inc", "longName": "Minerva Neurosciences, Inc.", "firstTradeDateEpochUtc": 1404221400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ceeb0642-b36f-3eda-bb3a-75cdc1b13e8a", "messageBoardId": "finmb_261133065", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.4399, "targetHighPrice": 5.0, "targetLowPrice": 5.0, "targetMeanPrice": 5.0, "targetMedianPrice": 5.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 30881000, "totalCashPerShare": 4.416, "ebitda": -26205152, "totalDebt": 86579048, "quickRatio": 7.347, "currentRatio": 7.472, "returnOnAssets": -0.28884, "freeCashflow": -17926034, "operatingCashflow": -20829020, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]